Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.45 |
| ▸ | HTR2C | P28335 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30076646 | 1.00 | HTR2A (0.45) | HTR2AHTR2CKDM4EMAPTNPC1 | |
| SCHEMBL2421457 | 0.82 | KDM4E (0.49) | HTR2AHTR2CKDM4EMAPTNPC1 | |
| SCHEMBL7292520 | 0.78 | MAPT (0.46) | HTR2AKDM4EMAPTNPC1PKM | |
| SCHEMBL11511852 | 0.76 | KDM4E (0.43) | HTR2AKDM4EMAPTNPC1PKM | |
| SCHEMBL9259549 | 0.75 | HTR2A (0.44) | HTR2AHTR2CKMT2ASIGMAR1HTR1A | |
| SCHEMBL9658744 | 0.75 | KDM4E (0.48) | HTR2AHTR2CKDM4EMAPTKMT2A | |
| SCHEMBL9658748 | 0.75 | KDM4E (0.48) | HTR2AHTR2CKDM4EMAPTKMT2A | |
| SCHEMBL19609005 | 0.72 | PIK3CA (0.39) | HTR2AHTR2CKDM4EMAPTKMT2A | |
| SCHEMBL3574670 | 0.71 | SRD5A2 (0.50) | ALDH1A1 | |
| SCHEMBL16453898 | 0.71 | GPR84 (0.41) | KDM4EMAPTNPC1PKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859615-B2 | Compounds, compositions and methods for reducing toxicity and treating or preventing diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-14 | — | — | US | claimed |
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-12-22 | — | — | US | claimed |
| EP-2331093-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | The Trustees of Columbia University in the City of New York (US) | 2011-06-15 | — | — | EP | claimed |
| US-20110124690-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-05-26 | — | — | US | claimed |
| WO-2010025272-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-03-04 | — | — | WO | claimed |
| WO-2009105123-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-08-27 | — | — | WO | claimed |
| WO-2008103916-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER | THE TRUSTEES OF COLUMBIA UNIVERISTY IN THE CITY OF NEW YORK (US) | 2008-08-28 | — | — | WO | claimed |
| US-20050244413-A1 | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents | ADOLF GUENTHER | 2005-11-03 | — | — | US | claimed |
| EP-1531869-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING MAYTANSINOID CD44 ANTIBODY IMMUNOCONJUGATES AND CHEMOTHERAPEUTIC AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 2005-05-25 | — | — | EP | claimed |
| US-20040192621-A1 | Anti-tumor agent | AJINOMOTO CO., INC (JP) | 2004-09-30 | — | — | US | claimed |
| US-20040126379-A1 | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-07-01 | — | — | US | claimed |
| EP-1407784-A1 | ANTITUMOR AGENTS | Ajinomoto Co., Inc. (JP) | 2004-04-14 | — | — | EP | claimed |
| WO-2004018000-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING MAYTANSINOID CD44 ANTIBODY IMMONOCONJUGATES AND CHEMOTHERAPEUTIC AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-03-04 | — | — | WO | claimed |
| EP-1391213-A1 | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents | Boehringer Ingelheim International GmbH (DE) | 2004-02-25 | — | — | EP | claimed |
| US-20030109500-A1 | Compositions and methods for use in targeting vascular destruction | MATEON THERAPEUTICS, INC. | 2003-06-12 | — | — | US | claimed |
| US-6538038-B1 | A method of treating a warm-blooded animal having a vascular proliferative disorder, comprising administering, to the animal, an amount of a prodrug of a tubulin binding agent, other than combretastatin A4 disodium phosphate to achieve | OXIGENE, INC. | 2003-03-25 | — | — | US | claimed |
| US-12180228-B2 | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-12-31 | — | — | US | disclosed |
| US-20230212195-A1 | COMPOUNDS, CONJUGATES, AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-07-06 | — | — | US | disclosed |
| WO-2002000215-A1 | SUBTYPE SELECTIVE MELATONERGICS | COGNETIX, INC. (US) | 2002-01-03 | — | — | WO | disclosed |
| WO-2002000215-A1 | SUBTYPE SELECTIVE MELATONERGICS | COGNETIX, INC. (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212195-A1 | COMPOUNDS, CONJUGATES, AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES AND USES THEREOF | DNPEP, DHPS, NPEPPS | HTR2A 307/4885HTR2C 477/4885KDM4E 2404/4885 |
| US-20110312904-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES | TUBA1C, TUBB1, TOP1 | HTR2A 4386/4885HTR2C 4379/4885KDM4E 4394/4885 |
| US-20030109500-A1 | Compositions and methods for use in targeting vascular destruction | ALPP, MVD, TYMP | HTR2A 4376/4885HTR2C 4505/4885KDM4E 2646/4885 |
| US-20110124690-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER | BDNF, NGF, NTRK2 | HTR2A 2170/4885HTR2C 1920/4885KDM4E 4722/4885 |
| US-20050244413-A1 | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents | CD44, EPCAM, FUT4 | HTR2A 3462/4885HTR2C 3925/4885KDM4E 3363/4885 |
| US-20040126379-A1 | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents | CD44, EPCAM, FUT4 | HTR2A 3462/4885HTR2C 3925/4885KDM4E 3363/4885 |
| US-20040192621-A1 | Anti-tumor agent | TUBB1, TUBB3, TUBB | HTR2A 4458/4885HTR2C 4816/4885KDM4E 4672/4885 |
| US-12180228-B2 | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof | DNPEP, DHPS, NPEPPS | HTR2A 307/4885HTR2C 477/4885KDM4E 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.